You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
One of the major inhibitory neurotransmitters in the mammalian CNS, predominantly active in the spinal cord and brain stem. Also acts as a modulator of excitatory amino acid transmission mediated by NMDA receptors.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 75.07. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||13.32 mL||66.6 mL||133.21 mL|
|5 mM||2.66 mL||13.32 mL||26.64 mL|
|10 mM||1.33 mL||6.66 mL||13.32 mL|
|50 mM||0.27 mL||1.33 mL||2.66 mL|
References are publications that support the biological activity of the product.
Betz (1991) Glycine receptors: heterogeneous and widespread in the mammalian brain. Trends Neurosci. 14 458 PMID: 1722365
Kuhse et al (1995) The inhibitory glycine receptor: architecture, synaptic localization and molecular pathology of a postsynaptic ion-channel complex. Curr.Opin.Neurobiol. 5 318 PMID: 7850154
Ascher and Johnson (1989) The NMDA receptor, its channel and its modulation by glycine. The NMDA Receptor (2nd edition). Eds. G.L.Collingr 109
Johnson and Ascher (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 529
If you know of a relevant reference for Glycine, please let us know.
View Related Products by Product Action
Keywords: Glycine, Glycine supplier, Endogenous, glycine, receptor, agonists, potentiator, co-transmitter, GlyR, Glycine, Receptors, Glutamate, NMDA, N-Methyl-D-Aspartate, iGluR, Ionotropic, 0219, Tocris Bioscience
4 Citations for Glycine
Citations are publications that use Tocris products. Selected citations for Glycine include:
Sivakumaran et al (2015) Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo. Front Cell Neurosci 35 8291 PMID: 26019342
Kenny et al (2009) The integrity of the glycine co-agonist binding site of N-MthD.-aspartate receptors is a functional quality control checkpoint for cell surface delivery. J Biol Chem 284 324 PMID: 18990687
Kaushal and Schlichter (2008) Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 28 2221 PMID: 18305255
Hangen et al (2018) Neuronal Activity and Intracellular Calcium Levels Regulate Intracellular Transport of Newly Synthesized AMPAR. Cell Rep 24 1001 PMID: 30044968
Do you know of a great paper that uses Glycine from Tocris? Please let us know.
Reviews for Glycine
Average Rating: 5 (Based on 1 Review.)
Have you used Glycine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Mixture of 100 microM of glycine + 100 microM NMDA was used to evoke an NMDA receptor response in outside-out patched excised from hippocampal neurons. Glycine displayed a clear co-agonist effect, as expected. Easily soluble, no problem if stored in frozen aliquots for more than half a year.
For experiments with NMDA receptors use of D-Serine is sometimes better.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.